Characteristics of patients carrying plasmid-mediated AmpC beta-lactamase- and ESBL-producing Enterobacteriaceae (each 39 patients); univariate logistic regression analysis to define risk factors for plasmid-mediated AmpC beta-lactamase producers.

Abbreviations: pAmpC, plasmid-mediated AmpC beta-lactamase; ESBL, Extended-Spectrum beta-Lactamase; OR, odds ratio; CI, confidence interval; MRE, multidrug-resistant Enterobacteriaceae; eGFR, estimated glomerular filtration rate; COPD, chronic obstructive pulmonary disease* Matching variables‡ Patients with known exposure status to antibiotic treatment: 32 in the pAmpC and 33 in the ESBL group§ >10 mg prednisone equivalent daily for >3 months† McCabe Score: 1 = non-fatal disease (supposed survival >5 years for >50% of patients with the disease), 2 = ultimately fatal disease (supposed survival 1–5 years for >50% of patients with the disease), 3 = rapidly fatal disease (supposed death within 1 year for >50% of patients with the disease)Characteristics of patients carrying plasmid-mediated AmpC beta-lactamase- and ESBL-producing Enterobacteriaceae (each 39 patients); univariate logistic regression analysis to define risk factors for plasmid-mediated AmpC beta-lactamase producers.